Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG (GALD – Research Report). The associated price target remains the same with CHF112.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s strong market performance and potential for future growth. The US sales volumes for Galderma’s product, Nemluvio, have consistently exceeded expectations, with a notable 5% week-over-week growth. This robust volume growth aligns with the firm’s optimistic projections, reinforcing confidence in the company’s market position.
Moreover, the average number of prescriptions, which count for two pens, is significantly higher than anticipated, suggesting strong demand and effective market penetration. While there remains some uncertainty regarding net pricing evolution, the current sales trajectory suggests that Galderma is well-positioned to maintain a competitive edge. These positive indicators contribute to the Buy rating, as they suggest a promising outlook for Galderma’s financial performance in the near future.